Persistent URL of this record https://hdl.handle.net/1887/113303
Documents
-
- Download
- 10.1136_annrheumdis-2015-209057
- Not Applicable (or Unknown)
- open access
In Collections
This item can be found in the following collections:
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
- All authors
- Emery, P.; Bingham, C.O.; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; Heijde, D. van der; Vollenhoven, R. van; Arendt, C.; Mountian, I.; Purcaru, O.; Tatla, D.; VanLunen, B.; Weinblatt, M.E.
- Date
- 2017-01-31
- Journal
- Annals of the Rheumatic Diseases
- Volume
- 76
- Issue
- 1
- Pages
- 96 - 104